Becton Dickinson is a global medical technology company that specializes in the development and manufacture of medical devices, instrument systems, and reagents
The company focuses on improving patient care and advancing healthcare delivery through its diverse product offerings, which include syringes, needles, blood collection systems, and diagnostic tools. With a strong commitment to innovation and quality, Becton Dickinson serves healthcare professionals and institutions around the world, facilitating safe and effective medical procedures and enhancing the overall health and well-being of patients.
Over the past six months, BD’s shares (currently trading at $224.85) have posted a disappointing 5.9% loss, well below the S&P 500’s 5.1% gain. This might have investors contemplating their next move.
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
Medical technology company Becton, Dickinson and Company (NYSEBDX)
will be announcing earnings results tomorrow before market open. Here’s what to look for.
Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company's worth by up to 30%.
BD (Becton, Dickinson and Company) (NYSEBDX), a leading global medical technology company, and Biosero, a developer of laboratory automation solutions to orchestrate scientific discoveries, today announced a framework collaboration agreement to enable and facilitate robotic arm integration with BD flow cytometry instruments to accelerate drug discovery and development.
We are looking for value in the Healthcare Sector because we are still in a strong bull market that has been not only one of the longest on record, but also has seen the S&P 500 get to one of its lofty valuations ever.
BD's Q4 sales rose 6.9% to $5.44 billion, beating estimates. EPS of $3.81 also topped forecasts. FY25 guidance includes $21.9 billion-$22.1 billion sales and EPS of $14.25-$14.60.
